Annual report
7317.TEDINET S100YI6P
Period2025-04-01 → 2026-03-31
Filed2026-06-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 155
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥9.8bn | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥9.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥8.4bn | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥7.2bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥5.6bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥2.1bn | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥2.0bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥2.2bn | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.1bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.3bn | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥675m | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥409m | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.0bn | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.1bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.5bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.6bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥953m | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥426m | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥165m | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥1.5bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥1.6bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥12.5bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥10.9bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥9.9bn | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥8.7bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥6.9bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.4bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥4.0bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥8.1bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥6.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.2bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥3.8bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥3.2bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.4bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.9bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.0bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.2bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.3bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.5bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.3bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥528m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥915m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥140m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.1bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥746m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥616m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.3bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥485m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥284m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥38m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥183m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.2bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥504m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥72.5 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥73.38 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥45.03 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥20.17 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥7.85 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥71.9 | 2025-04-01 → 2026-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥72.55 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥44.43 | 2023-04-01 → 2024-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥20.02 | 2022-04-01 → 2023-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥7.75 | 2021-04-01 → 2022-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥380.42 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥324.88 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥244.72 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥178.69 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥153.44 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 65.2% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.3% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.2% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.0% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 20.6% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 25.7% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 21.3% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.1% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.5% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,552 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 1,403 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 1,367 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 1,383 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 1,442 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥3.8bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥3.3bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥3.2bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.0bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.4bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | −¥93m | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥149m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥472m | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥903m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥347m | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥68m | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥31m | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥311m | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥637m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥305m | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥636m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥206m | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥320m | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥4m | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥5.2bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥4.8bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥4.2bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.1bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥3.1bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.2bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥3.0bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.9bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.8bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.2bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥1.0bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.3bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.2bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.6bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥14.27 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥29.89 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥9.74 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-15.16 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-0.2 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥14.15 | 2025-04-01 → 2026-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥29.55 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥9.61 | 2023-04-01 → 2024-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥10 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥2.5 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥5 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥5 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥90.01 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥85.11 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥56.75 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥47.4 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥63.58 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 37.3% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.0% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.9% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 24.5% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.8% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 16.3% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 42.1% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 18.7% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | -27.3% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | -0.3% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 21,427,600 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 21,342,800 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 21,223,200 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,281,800 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,275,400 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 46 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 43 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 44 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 39 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 39 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2025-04-01 → 2026-03-31 | ¥102m |
| Otherother segments | revenue external | 2025-04-01 → 2026-03-31 | ¥102m |
| Otherother segments | segment assets | at 2026-03-31 | ¥7m |
| Otherother segments | segment profit | 2025-04-01 → 2026-03-31 | −¥35m |
| Reconciling Itemsreconciling | capex | 2025-04-01 → 2026-03-31 | ¥367m |
| Reconciling Itemsreconciling | depreciation | 2025-04-01 → 2026-03-31 | ¥10m |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | ¥2.0bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥356m |
| Medical Healthcarereportable segment | capex | 2025-04-01 → 2026-03-31 | ¥384m |
| Medical Healthcarereportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥96m |
| Medical Healthcarereportable segment | employees | at 2026-03-31 | 583 pure |
| Medical Healthcarereportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥6.8bn |
| Medical Healthcarereportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥6.8bn |
| Medical Healthcarereportable segment | segment assets | at 2026-03-31 | ¥5.5bn |
| Medical Healthcarereportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥2.1bn |
| Safety Systemreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥162m |
| Safety Systemreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥80m |
| Safety Systemreportable segment | employees | at 2026-03-31 | 960 pure |
| Safety Systemreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥2.9bn |
| Safety Systemreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥2.9bn |
| Safety Systemreportable segment | segment assets | at 2026-03-31 | ¥5.0bn |
| Safety Systemreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥397m |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-04-01 → 2026-03-31 | ¥546m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-04-01 → 2026-03-31 | ¥176m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2026-03-31 | ¥9.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2026-03-31 | ¥9.8bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2026-03-31 | ¥10.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2026-03-31 | ¥2.5bn |
| Otherother segments | revenue | 2024-04-01 → 2025-03-31 | ¥129m |
| Otherother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥129m |
| Otherother segments | segment assets | at 2025-03-31 | ¥55m |
| Otherother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥31m |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥18m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥3m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥1.9bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥318m |
| Medical Healthcarereportable segment | capex | 2024-04-01 → 2025-03-31 | ¥193m |
| Medical Healthcarereportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥83m |
| Medical Healthcarereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥6.1bn |
| Medical Healthcarereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥6.1bn |
| Medical Healthcarereportable segment | segment assets | at 2025-03-31 | ¥4.8bn |
| Medical Healthcarereportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥2.0bn |
| Safety Systemreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥319m |
| Safety Systemreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥106m |
| Safety Systemreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥3.4bn |
| Safety Systemreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥3.4bn |
| Safety Systemreportable segment | segment assets | at 2025-03-31 | ¥4.1bn |
| Safety Systemreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥253m |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥512m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥189m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥9.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥9.6bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥9.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥2.3bn |
| Medical Healthcarereportable segment | employees | at 2026-03-31 | 13 pure |
| Safety Systemreportable segment | employees | at 2026-03-31 | 24 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,407
| Item | Context | Value | Unit |
|---|---|---|---|
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 12 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 2.809 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 3.408 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 7.413 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 6.846 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 8.331 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 1.478 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.564 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 2.210 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 2.176 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 2.930 | |
| Gross scope1 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior2YearDuration | 213.54 | |
| Gross scope1 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior1YearDuration | 223.25 | |
| Gross scope1 greenhouse gas emissions scope1 and2 greenhouse gas emissions | CurrentYearDuration | 119.06 | |
| Gross scope2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior2YearDuration | 3289.20 | |
| Gross scope2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior1YearDuration | 2957.55 | |
| Gross scope2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | CurrentYearDuration | 1963.28 | |
| Gross scope1 and2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior2YearDuration | 3502.74 | |
| Gross scope1 and2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior1YearDuration | 3180.80 | |
| Gross scope1 and2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | CurrentYearDuration | 2082.34 | |
| Research and development expenses research and development activities | CurrentYearDuration | 76736000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 913043000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E35560-000MedicalHealthcareReportableSegmentMember | 384204000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E35560-000SafetySystemReportableSegmentMember | 161954000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_CorporateSharedMember | 366883000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 21427600 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 21505200 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 21427600 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 21505200 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 1 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 17 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 12 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 27 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 5 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 1226 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 1288 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 76 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 17662 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 64691 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 16581 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 11 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 115216 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 214237 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 3900 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.0004 | |
| Percentage of shareholdings financial service providers | CurrentYearInstant_OrdinaryShareMember | 0.0824 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |